Palliative care for people living with cardiac disease by unknown
KARDIOLOGIA POLSKA 2020; 78 (4)364
to address the needs of noncancer patients, in‑
cluding those with cardiac disease.1,2 The Eu‑
ropean Association for Palliative Care (EAPC) 
and the World Health Organization define PC as 
Introduction and basic definitions Pallia‑
tive care (PC) was conceptualized as a holistic 
approach to the care of people at the end stage 


















Many cardiovascular diseases lead to heart failure, which is a progressive syndrome causing significant 
distress and limiting the quality of life, despite optimal cardiologic treatment. It is estimated that about 
26 000 people in Poland suffer from advanced heart failure, and this number is growing. That is why 
palliative care (PC) dedicated to people living with end ‑stage cardiac diseases should be urgently 
implemented in Poland. Well ‑organized PC may not only relieve symptoms and improve quality of life in 
people living with cardiac diseases not responding to treatment but also support patients and their families 
during the dying process. Palliative care in patients with cardiac diseases should be continued during 
the end‑of‑life period. It should be implemented regardless of prognosis, and adjusted to patients’ needs. 
Two approaches to PC are presented in this expert opinion. The first one (generic) is provided by all medical 
professionals incorporating PC principles into the usual patient care. The second approach, namely, 
specialized PC, is ensured by a multiprofessional team or at least a PC specialist who received appropriate 
training in PC. The model of needs‑based (not prognosis‑based) implementation of PC is discussed in this 
paper. Symptom control, support in decision‑making, and sensitive, open communication are considered 
integral elements of PC interventions.  Medical professionals developing PC in Poland should think about 
groups of patients with special needs like those with valvular heart disease, grown ‑up congenital heart 
disease, and pulmonary arterial hypertension, as well as elderly people. This consensus document presents 
main recommendations for future PC organization in Poland. Among others, we suggest changing the Polish 
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the active, total care of a person whose disease is 
not responsive to treatment.3,4 Of note, the un‑
responsiveness to treatment does not refer to 
a situation in which “nothing more can be done.” 
What it actually means is that therapy has in‑
sufficient efficacy and does not satisfactorily al‑
leviate symptoms nor does it limit the disease 
burden. With the current definition of PC, EAPC 
promotes a new perspective on healthcare. It 
advocates extending the scope of healthcare 
beyond prolonging life and suggests a meticu‑
lous care of all components of patient’s quali‑
ty of life (QoL) to enable them to live a full life 
to the greatest extent possible. Currently, PC 
is considered appropriate during the whole life 
span of a patient with cardiac disease, unrelated 
to expected prognosis, and should be provided 
according to the existing needs (FIGURE 1).
Palliative care is an interdisciplinary approach 
focused on the ill person and his or her relatives, 
addressing patients’ needs wherever they are, 
whether at home or in any healthcare institu‑
tion.3 Palliative care services can be defined as ge‑
neric (known as the PC approach) or specialized. 
Generic PC is provided by all healthcare profes‑
sionals who apply PC principles to the usual clini‑
cal practice. Specialized PC services are delivered 
by a multiprofessional team, or at least a PC spe‑
cialist, who received appropriate training in PC. 
Palliative care approach can help the majority of 
people living with heart failure (HF) meet their 
needs. A small group of patients, who have com‑
plex needs or problems persisting despite receiv‑
ing generic PC, need specialized PC.5,6
Triggers for palliative care in patients with 
cardiac disease When to start PC is one of 
the most relevant issues defining the cooper‑
ation between cardiologists and PC specialists. 
The majority of validated tools aimed to identi‑
fy patients who should receive PC, like Support‑
ive and Palliative Care Indicators Tool (SPICT) 
or “surprise question,” unfortunately indicate 
only those at risk of deterioration or death.7,8 
However, as mentioned above, the rationale of 
PC nowadays should not be helping only patients 
at risk of deterioration or death but recognizing 
unaddressed needs, which are independent from 
these risks.1,3 The Needs Assessment Tool: Pro‑
gressive Disease—Heart Failure (NAT: PD ‑HF) 
is a validated tool, which supports healthcare 
professionals in the evaluation of PC needs in 
patients with cardiac disease and corresponds 
with the current perspective on PC.9-11 It eval‑
uates the needs of patients and caregivers, in‑
cluding their wellbeing and ability to care for pa‑
tients. Confirmed disease progression and ex‑
panding treatment, particularly if the disease 
is burdensome or associated with high deterio‑
ration risk, should trigger the evaluation of PC 
needs and initiate the delivery of PC services 
if appropriate.2 The possible triggers initiating 
the evaluation of PC needs and the flow ‑chart 
showing how to evaluate patients’ need for PC 
are presented in FIGURE 2.
Symptom evaluation After symptoms or 
problems were identified, they have to be as‑
sessed and appropriately treated by the provid‑
ers of PC, that is, either the core team (applying 
the PC approach) or a PC specialist or team (ap‑
plying the specialized PC).2 Optimally, the as‑
sessment should be performed using validat‑
ed tools. The most frequently used tools for 
symptom evaluation are the Edmonton Symp‑
tom Assessment System (ESAS), which deter‑
mines the intensity of 9 symptoms most fre‑
quently seen in PC patients and 1 self ‑defined 
NYHA I
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FIGURE 1 The clinical course of heart failure with associated types and intensities of available therapies. Adapted from Sobanski101 (figure in press)
 Abbreviations: NYHA, New York Heart Association
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FIGURE 2 Patient’s needs assessment—flowchart. Reprinted with permission from the Oxford University Press2
 Abbreviations: ACP, advance care planning; CIED, cardiac implantable electronic device; HF, heart failure; ICD, implantable 
cardioverter-defibrillator; NYHA, New York Heart Association; PC, palliative care
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  *Triggers for PC assessment
 I. Significant change in heart failure trajectory:
  • New HF (incidental HF) with refractory, severe symptoms before discharge
  • Before ICD / CIED implantation or replacement
  • Qualification for heart transplantation or mechanic circulatory support
  • Consideration of high risk or high burden intervention or treatment
  • After resuscitated sudden cardiac death
  • Signs or symptoms of advanced HF: especially with risk markers or fulfilling criteria for referral to tertiary cardiac centres e.g., 
NYHA class IlI / IV, appetite / weight loss, physical wasting, initiation of intravenous inotropes, more than one unplanned 
hospitalization or visit due to decompensated HF within 12 months.
 II. Periodic HF follow up or significant changes in health status:
  • Periodic HF visit (in stable condition at least yearly check up)
  • Essential changes in health sta tus (new significant comorb idit y)
 III. Patient / family related factors:
  • Desire for additional communication
  • Request for excessive medical interventions
  • Request by or excessive burden of relatives / informal caregivers
  • Patient declining / dying wit h difficulties in acknowledging it
  • Request to hasten death / suicidal statements
  • Request of family or team caring for patient
  • Substantial change in next of kin circumstances (like new illness or death of spouse, or caregiver)
  • Declining ability to provide self-care
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HF and ultimately die (FIGURE 1). Not every per‑
son living with HF dies of it, as some patients 
die of other diseases, with HF being a concom‑
itant disease. The proportion of noncardiac or 
non ‑HF–related deaths differs according to age 
and HF severity and form (HF with preserved, 
midrange, or reduced ejection fraction). Patients 
with HF with preserved ejection fraction fre‑
quently die of a concomitant noncardiovascular 
disease (mainly malignant).32 In other patients, 
cardiovascular deaths are reported, which can 
be specified as, among others, sudden cardiac 
death (affecting a significant proportion of peo‑
ple living with HF, including those with less ad‑
vanced stages of HF), HF ‑related deaths, acute 
myocardial infarction–related death, and acute 
cerebrovascular death. The specific HF ‑related 
deaths can be further classified as end ‑stage 
HF with or without secondary end ‑organ fail‑
ure (kidney or liver failure).33
Palliative care and symptom management 
Symptom management is an integral part of 
PC in patients with HF. Symptoms occurring 
in this population can be related to HF (con‑
gestion and limited organ perfusion due to de‑
creased cardiac output, resulting in limited ex‑
ercise capacity and / or dyspnea), secondary to 
HF (fatigue, anxiety), caused by a concomitant 
disease (pain), or have complex etiology (cogni‑
tive impairment, cachexia). Dyspnea at rest or 
on slight exertion is an almost universal symp‑
tom of advanced HF, and, surprisingly, pain is 
very common in patients with HF. The princi‑
ples of symptom management in PC of patients 
with HF are summarized in the recent EAPC po‑
sition statement.2
Management of patients with cardiac im-
plantable electronic devices A growing num‑
ber of people live with cardiac implantable elec‑
tronic devices (CIEDs). The umbrella term CIED 
encompasses different devices, and each of them 
delivers specific treatment: 1) pacemakers, which 
deliver antibradycardia pacing and thus pre‑
vent symptoms of bradycardia or cessation of 
heartbeat; 2) cardiac resynchronization therapy 
(CRT) devices, which stimulate and synchronize 
the contractility of the left ventricle and may sig‑
nificantly improve its function; 3) implantable 
cardioverter ‑defibrillators (ICDs), which have 
several functions to cease tachyarrhythmia (ad‑
ditionally, they can deliver antibradycardia pac‑
ing); 4) a combination of 2) and 3), that is, CRT 
devices with defibrillator (CRT ‑D); to distinguish 
CRT ‑D from devices that deliver resynchroniza‑
tion pacing only, the name CRT ‑P is used.
Some functions of CIEDs, normally perceived 
as life ‑saving, can negatively influence the quali‑
ty of the dying process. That is why selected CIED 
functions should be considered for deactiva‑
tion if patient’s death is inevitable. Appropriate 
symptom,12,13 and the Distress Thermometer, 
which aims to assess psychosocial and spiritu‑
al problems.14 The Hospital Anxiety and Depres‑
sion Scale (HADS)15,16 and the Functional As‑
sessment of Chronic Illness Therapy ‑Spiritual 
Wellbeing (FACIT ‑Sp) are further assessment 
tools, which are frequently used in medical prac‑
tice.17 Before or at least in parallel with starting 
symptomatic treatment or palliative care in‑
terventions, every effort should be made to op‑
timize cardiac treatment. Palliative care inter‑
ventions, on top of this, reinforce the meticu‑
lous efforts to prolong life with the best quali‑
ty possible.18 Unfortunately, the outdated view 
that the disease ‑specific treatment has to be ex‑
hausted, stopped, or limited before starting PC 
is still considered valid by laymen and non ‑PC 
professionals. The currently advocated coexis‑
tence of both approaches in the treatment of pa‑
tients with cardiac disease is depicted in FIGURE 1.
Elements of palliative care interventions 
The key elements of PC include symptom man‑
agement, support in decision making includ‑
ing advance care planning (ACP), social support, 
spiritual care, and care of the dying patient, as 
well as bereavement counselling for families.1,19 
The components of PC that may actually be ap‑
plied should be tailored to the existing needs 
and can differ substantially at particular stages 
of disease progression. Many patients with ad‑
vanced cardiac disease suffer from pain, dyspnea, 
depression, and other symptoms surprisingly 
similar to those reported by patients receiving 
PC due to other progressive diseases, including 
cancer.13,20-23 Growing data show that timely im‑
plemented PC successfully alleviates symptoms 
and improves QoL in people with HF, without 
shortening their lives.18,24-27 What is more, effec‑
tive pain management has been recently shown 
to prolong life in patients with cardiovascular 
diseases.28-30 The need for psychosocial support 
and physical therapy are generally well‑recog‑
nized and accepted indications for PC. Address‑
ing patients’ spiritual needs usually escapes at‑
tention of healthcare professionals but should 
be a standard element of patient ‑centered care.31
Palliative care and the trajectory of living 
with heart failure and dying of this disease 
Heart failure is a progressive syndrome and 
an end stage of numerous cardiovascular dis‑
eases. At first presentation, patients usually have 
severe symptoms on slight exertion or at rest 
(New York Heart Association class III or IV). In 
the minority of cases, patients’ condition deteri‑
orates quickly and they die shortly after the first 
HF ‑related hospitalization. However, the major‑
ity of patients show improvement during the in‑
dex hospitalization and reach a sort of plateau, 
usually disrupted by acute decompensations, 
and, after months or years, develop end ‑stage 
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the device activities but wants to avoid suffering, 
leaving only ATP active, prolonging detection 
time or limiting the maximal number of high‑
‑voltage interventions can be an option. If ATP 
is left active, the risk of accelerating tachycar‑
dia should be considered. In the case of CRT‑D, 
antybradycardia pacing and, even more impor‑
tantly, resynchronization therapy should be left 
fully active, as discussed above.
In the context of EoL and PC, 4 scenarios re‑
garding the modification of CIED function can 
be considered:40,41 1) deactivating the shock‑
ing function or all antitachycardia functions of 
ICD / CRT ‑D devices; 2) suspending antitachy‑
caria therapies emergently using a magnet; in 
patients imminently dying unless the preferred 
electronic deactivation can be performed; 3) 
abandoning ICD replacement after battery de‑
pletion; 4) deactivating antibradycardia pacing 
or stopping CRT (this can be considered only ex‑
eptionally as a PC intervention).
Considering the modification of CIED activ‑
ity, local medical, ethical, medico ‑legal, spiri‑
tual, and religious issues need to be respected. 
The Polish law permits modification of (select‑
ed) ICD functions. Specifically, the Act on Pa‑
tient Rights and the Act on the Patient Rights 
Ombudsman emphasize patients’ right to die in 
peace and dignity.
Communicating with people living with 
heart failure Sensitive and open communi‑
cation is considered an integral part of PC in‑
terventions; in particular, discussing prognosis, 
disease progression, and, if necessary, the risk 
and pattern of health deterioration and dying. 
Disease management options are usually well 
discussed with patients by the Heart Team, but 
the risk of deterioration and dying is hardly ex‑
plained. Nevertheless, these issues are relevant 
and should be covered.42-44 Discussing realistic 
prognosis allows ill people to make plans and 
to maintain realistic hope. The physician should 
initiate a conversation about patient’s future 
condition, especially EoL, in advance, before 
patient’s condition deteriorates, making his or 
her active participation difficult.45-47 The commu‑
nication process is often challenging for both 
the patient and the physician. To make sure 
that the quality of communication is high and 
to facilitate the active involvement of patients 
in the decision ‑making process, healthcare pro‑
fessionals working in cardiology should receive 
training in communication skills. This will help 
them to feel more comfortable, especially in 
challenging situations.48 Personal beliefs and 
values may influence the ability of healthcare 
professionals to communicate with patients 
at the EoL and care for them. Concerns about 
death and dying may be a reason for avoiding 
these topics or making the discussion unclear. 
It is important to acknowledge this fact and 
modification of CIED activity should be per‑
formed when patient’s death is predictable, but 
this needs to be communicated much earlier—
optimally, even before implantation. Decision 
making regarding the modification of CIEDs 
should be an integral part of ACP. Despite these 
recommendations, the appropriate communica‑
tion and timely modification of CIEDs are not 
common. According to a European survey, only 
6% of patients reported that they discussed 
the modification of CIED activity at the end of 
life (EoL) with their doctors in detail, and 12% of 
respondents remembered that this topic was cov‑
ered only briefly.34 As a result, most patients ap‑
proaching predictable death have their ICDs fully 
active, even those who have a do ‑not ‑resuscitate 
order.35,36 In 35% of patients with ICDs, ventricu‑
lar tachyarrhythmia (including electrical storm) 
was recorded during the last hours of life, and 
31% received potentially painful high ‑voltage 
therapy in the last 24 hours of life.35
Pacemakers deliver cardiac pacing, which is 
unnoticeable for patients. After ceasing this 
stimulation, patients lose protection against 
the symptoms of temporary (ie, dizziness, dys‑
pnea, and syncope) or chronic bradycardia (ie, 
anginal pain or aggravation of HF symptoms). 
The continuation of antibradycardia pacing nei‑
ther causes suffering nor prolongs the dying pro‑
cess (besides very exceptional situations like ir‑
reversible brain injury), and, apart from that, its 
cessation can precipitate the above mentioned 
symptoms. That is why discontinuing pacing 
cannot be considered a PC intervention in a dy‑
ing person.37-40
In patients responding to CRT and show‑
ing improvement of HF symptoms, even an ac‑
cidental loss of effective stimulation leads to 
the abrupt deterioration of cardiac function and 
may precipitate fulminant, acute HF symptoms 
like dyspnea or acute pulmonary edema. De‑
vice reprogramming, which stops resynchro‑
nizing stimulation, would evoke similar acute 
HF symptoms. Therefore, it should be strong‑
ly discouraged and cannot be regarded as a PC 
intervention.38-40
Implantable cardioverter ‑defibrillators and 
CRT ‑D devices deliver low ‑voltage therapies 
(antitachycardia pacing [ATP]) unnoticeable 
for patients or usually painful high ‑voltage in‑
terventions, ie, cardioversion and defibrillation. 
The modification of antitachyarrhythmia ther‑
apy in patients approaching death, in whom 
the underlying diseases cannot be successfully 
treated, aims to avoid suffering precipitated by 
the CIED interventions or to prevent prolonga‑
tion of the dying process (futile therapy). Aban‑
doning high ‑voltage interventions is sufficient 
to avoid patients’ suffering, and ceasing all an‑
titachycardia therapies should be considered ap‑
propriate to prevent prolongation of the dying 
process. If the patient prefers not to lose any of 
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End of life in people living with heart failure 
The concept of EoL refers to the period of pro‑
gressive disease deterioration, which pre‑
cedes imminent death and cannot be stopped 
by adjusting disease ‑specific treatment. Con‑
trary to common belief, the EoL lasts weeks or 
even months and is characterized by progres‑
sive decline and physical wasting. In contrast, 
the phase of active dying is much shorter, lim‑
ited to the last days or hours of patient’s life, 
and is characterized by signs and symptoms of 
imminent death.58 This last phase is a dynam‑
ic process when consciousness and symptoms 
fluctuate, previously observed symptoms disap‑
pear, and usually the new ones occur. The time‑
ly recognition of the EoL and dying is of utmost 
importance, as treatment and care need to be 
properly adjusted, and the observation should 
be communicated to the patient and his or her 
loved ones openly and in a compassionate way. 
Critical re ‑evaluation of treatment goals, ad‑
justing the ongoing treatment, and starting new 
management focused on symptom control are 
needed.59,60 The modification of CIEDs should be 
performed at this time at the latest, based on 
conclusions from previous conversations.38,61 In 
the dying phase, frequent (at least every 4 hours), 
careful monitoring of symptoms, suffering, and 
need for PC interventions is recommended. Ba‑
sic bereavement counselling for both the dying 
person and the family may be needed.
Palliative care in selected patient popula-
tions Patients with valvular heart disease In ec‑
onomically developed countries, valvular heart 
disease is often diagnosed for the first time at ad‑
vanced age.62,63 Aortic stenosis, the most com‑
mon primary valvular disease, requires surgi‑
cal or catheter ‑based treatment if it has a se‑
vere course.63 The Heart Team should discuss 
the best suitable treatment option for a given 
person. For those who are too ill, too frail, who 
do not consent to valve repair or replacement, 
applying symptomatic treatment, including PC 
if needed, can be the optimal solution. For this 
reason, the members of a PC team, or at least a PC 
specialist, should be included in the core Heart 
Team.64 In such cases, PC can include assistance 
in the decision ‑making process, communicating 
alternative, noninterventional treatment options, 
ACP, or delivering care for the dying in the case 
of serious complications.64,65 Further studies are 
needed to assess the impact, efficacy, and safety 
of specific PC interventions in the population of 
patients with valvular heart disease.
Elderly patients with heart failure Heart fail‑
ure is regarded as a disease of the elderly and, in 
most cases, it is associated with concomitant dis‑
eases such as coronary artery disease, valvular 
heart disease, chronic obstructive pulmonary 
disease, renal failure, diabetes, or anemia.66-68 It 
involve other healthcare professionals if need‑
ed. Of note, showing emotions is not a sign of 
unprofessional behavior or weakness.47,49-51 El‑
ements that should be included in the commu‑
nication with patients living with HF are pre‑
sented in TABLE 1.
Setting up communication
1	 Build a collaborative team. The team is re‑
sponsible for delivering care, which should con‑
sider patients’ individual values and preferenc‑
es.52 Tasks and responsibilities need to be ap‑
propriately split among professionals of vari‑
ous specialties, taking into account different 
fields of patients’ needs.53 The communication 
pathways between caregivers and team mem‑
bers should be established.54
2	 Evaluate the situation. Components crucial 
for decision making should be reviewed and dis‑
cussed if needed. They include patient’s condi‑
tion and values related to healthcare, aims and 
preferences, concerns about QoL, and the con‑
textual issues.49,51
3	 Prepare structured discussion and consider 
the following issues:
Who? Who should be present during the con‑
versation? Ask the patient who he or she wants 
to assist him or her.
What? Be aware of patient’s personal goals 
before starting the conversation. Get ready for 
new issues that can appear during the conver‑
sation and affect the discussion.
When? Take your time and complete 
the  planned discussion calmly. Sit during 
the conversation, showing the patient that you 
have time needed to discuss all issues. Good 
communication is time ‑consuming and a sin‑
gle session takes 20 to 30 minutes on average.55
Where? Talk with the patient in a quiet room; 
if the conversation has to held at the bedside, 
ensure that the place is as quiet and intimate 
as possible.
How? Prepare a plan for discussion. Write 
down conversation goals and pay attention 
to the reactions of your interlocutor. Be flex‑
ible, as patient’s needs may change during 
the conversation.45,50,53,56,57
TABLE 1 Communication with patients living with heart failure48,49,99,100
1. What patients and caregivers need to know:
• Diagnosis and disease stage
• Anticipated disease progression and related problems
2. Challenging issues associated with heart failure:
• Uncertain prognosis
• Progression of heart failure and health deterioration are inevitable but cardiac 
treatment can usually alleviate symptoms, slowing patient’s decline and improving 
survival.
• The risk of cardiac arrest / sudden cardiac death; patient’s preferences regarding 
resuscitation need to be discussed (the likelihood of successful resuscitation should 
be addressed).
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In most cases, life expectancy in patients with 
GUCH is still shorter than in the general popula‑
tion. One ‑third of deaths occur suddenly, where‑
as the majority of patients die after progressive 
health deterioration over a few months, mainly of 
chronic HF.80 Such patients could benefit from in‑
corporating PC into cardiac care.83-86 The models of 
PC provision in this population still need to be es‑
tablished, respecting local traditions and interna‑
tional experiences. Palliative care should probably 
be provided as an element of comprehensive care 
and delivered by the team who used to take care of 
a given person and whom the patient trusts. For 
this reason, healthcare professionals with essen‑
tial PC skills should be a part of the core team in 
the GUCH centers or closely cooperate with them.
As presented above, discussing EoL ‑related is‑
sues in advance helps to deliver care in line with 
person’s individual goals and values and to im‑
prove the QoL and dying.83,84,86 Many patients with 
GUCH prefer to be involved in EoL decision making 
at an early stage of the disease course, and a ma‑
jority of them even expect such discussions.83,84
Patients with pulmonary arterial hypertension 
The currently available treatment of pulmonary 
arterial hypertension (PAH) has markedly im‑
proved patients’ survival. Nevertheless, PAH re‑
mains an incurable disease, which significantly 
impairs patients’ QoL. People living with PAH 
and their families experience emotional, phys‑
ical, social, and spiritual distress. In this pop‑
ulation, PC should focus on symptomatic pa‑
tients with functional New York Heart Asso‑
ciation class III or IV despite maximal medical 
therapy. Usually, they are frequently hospital‑
ized due to worsening of PAH ‑related symptoms. 
In Poland, the number of patients newly diag‑
nosed with PAH can be estimated as 100 cases 
per year. The usual care for this group includes 
home oxygen therapy, use of parenteral diuret‑
ics to alleviate symptoms of right ventricular 
HF, and surveillance over the use of parenteral 
prostanoids. The most common goals for PC in 
this population are the amelioration of dyspnea, 
treatment of depression and anxiety, multidirec‑
tional support for the family including commu‑
nicating disease progression and the expected 
pattern of health deterioration in addition to 
discussing disease ‑specific treatment options. 
Social and spiritual needs of patients and their 
relatives should be addressed as well. According 
to the current guidelines on the management of 
PAH, a PC specialist should be the core mem‑
ber of an interdisciplinary team taking care of 
the patient, together with a home nurse, a social 
worker, and a spiritual care specialist.87
Palliative care resources in Poland In Poland, 
the principles of PC were introduced at the end 
of the 20th century. The Polish Society for Pal‑
liative Medicine (Polish: Polskie Towarzystwo 
is sometimes difficult to differentiate symptoms 
of HF from those related to other diseases or age‑
ing. At advanced age, the prevalence of frailty syn‑
drome and other geriatric syndromes, such as de‑
pression, dementia, chronic pain, incontinence, 
limitations in mobility, and difficulty perform‑
ing basic self ‑care activities, increases.69-71 More‑
over, the social network is frequently impaired, 
and the informal caregivers do not manage to pro‑
vide sufficient care. Multimorbidity is inseparably 
associated with polypharmacy and the fragmen‑
tation of medical care provided by different spe‑
cialists. Of note, it is frequently difficult to indi‑
cate the doctor responsible for patient’s care and 
to make decision about deprescribing unnecessary 
drugs. Discussing issues around the QoL and EoL 
preferences with elderly patients is significantly 
hindered by their cognitive disorders, lower mood 
and worsened functional status, symptoms of oth‑
er diseases, and lack of social support.72
Finally, the choice, dosage, and administra‑
tion of analgesics should be modified in elderly 
patients with HF.73-75
Patients with grown ‑up congenital heart disease 
Congenital heart disease occurs in approximate‑
ly 0.8% of live births. Successful surgical and per‑
cutaneous interventions at young age resulted in 
a growing population of young adults who require 
lifelong both cardiac and noncardiac care,76,77 in‑
cluding PC in more complex situations.78-80 The ac‑
cess to optimal, comprehensive care for people 
living with grown ‑up congenital heart disease 
(GUCH) should be regarded as a standard ele‑
ment of medical care and social responsibility.
In Poland, there are approximately 80 000 
to 100 000 patients with GUCH. An annual in‑
crease of approximately 2240 cases can be an‑
ticipated, assuming that 80% of the current‑
ly born neonates with congenital heart disease 
survive to adulthood. According to internation‑
al data, 20% to 25% of the whole population of 
patients with GUCH has complex problems and 
requires lifelong expert care in dedicated centers, 
whereas 35% to 40% of this population needs 
expert consultations. Other patients with sim‑
ple or cured heart defects need specialist con‑
sultations only rarely.
Patients with functionally univentricular heart, 
who underwent the Fontan procedure, have to 
deal with the most complex problems. This in‑
tervention allows the affected patients to sur‑
vive, however, with multiorgan damage leading to 
significant morbidity and mortality in long ‑term 
follow ‑up.81,82 In many cases, the management of 
late complications is possible but the final deteri‑
oration inevitable. Heart transplantation can be 
considered an ultimate therapeutic option, but it 
is accessible only for the minority of patients. Pa‑
tients with the Fontan circulation who experience 
late complications could benefit from PC deliv‑
ered in parallel with cardiac treatment and care.82
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model of care, including PC, for patients with 
cardiac disease and their families has not been 
defined so far. However, patient care delivered 
by a cardiologist and / or Heart Team consult‑
ing PC specialists seems to be the most appro‑
priate solution, preferred by patients. In this 
model of care, patients receive comprehensive 
care from the team they trust, which is in line 
with their existing needs. A cardiologist and / or 
Heart Team continues to provide optimized car‑
diac care, whereas a PC specialist or PC team fo‑
cuses on symptom management, provides psy‑
chosocial and spiritual support, and helps with 
shared decision making (including ACP), and fi‑
nally takes care of the dying person if appropri‑
ate. In the last phase of patient’s life, PC provid‑
ers can take the lead in care.55,96,97 This kind of 
care is appropriate in both in‑ and out ‑patient 
settings. If the PC team has been involved dur‑
ing patient’s hospital stay, PC can be continued 
after discharge if needed, based on PC outpa‑
tient clinics, in addition to usual cardiac care.
Cardiac centers should cooperate with special‑
ized PC units or, at least, a PC specialist should 
be a member of the core Heart Team. The Ameri‑
can authorities (Medicare and Joint Commission) 
require a PC specialist to be a member of a team 
responsible for mechanical circulatory support 
being an element of target therapy programs.98 
In the primary care settings, care can be deliv‑
ered by general practitioners, who should ap‑
ply the principles of generic PC and receive sup‑
port from a cardiologist and a PC specialist (or 
a PC team) according to the existing needs. This 
model is particularly applicable in patients who 
require care of several specialists and / or can‑
not use services delivered by outpatient clinics. 
In several countries, general practitioners and 
family nurses play a key role in the care of pa‑
tients with advanced cardiac disease. Optimally, 
nurses should have experience in both cardiolo‑
gy and PC. For some patients, particularly those 
with relevant comorbidities or slowly progress‑
ing cardiovascular diseases and a prolonged EoL 
period, hospices with home ‑like inpatient units 
or home care can be the most appropriate model 
of care. In such models, close cooperation with 
cardiology specialists is mandatory.
Main recommendations for Poland 
• There is an urgent need to change the rules of 
reimbursement of PC services by NFZ in Po‑
land and the list of diseases should include 
other ICD‑10 codes related to cardiac disease, 
heart failure (I50) in particular.
• Medical personnel in the existing hospices, 
which signed contracts with NFZ, should be 
trained in delivering care to patients with 
cardiac disease.
• Palliative care should be included in the cur‑
riculum of cardiology specialist training and 
postgraduate education.
Medycyny Paliatywnej [PTMP]) was established 
in 2002. Since 2003, palliative medicine has been 
a medical specialty, and since 2006 also a nurs‑
ing specialty. In total, nearly 500 physicians and 
900 nurses are specialized in palliative medi‑
cine. In Poland, PC is reimbursed by the Polish 
National Health Fund (Polish: Narodowy Fun‑
dusz Zdrowia [NFZ]). According to NFZ, pallia‑
tive services were reimbursed in 2017 by 142 out‑
patient clinics, 486 home hospices, 67 home hos‑
pices for children, and 180 stationary hospices. 
Some of them operate as nongovernmental in‑
stitutions and their services are not reimbursed 
by the general health insurance. According to 
the Polish Ministry of Health, 788 PC units and 
hospices were registered in Poland in 2017. Based 
on the International Classification of Diseases and 
Related Health Problems, Tenth Revision [ICD‑10], 
NFZ specified disease entities, for which PC is re‑
imbursed, and, unfortunately, HF has not been 
included. Cardiomyopathy is the only ICD‑10 en‑
tity related to cardiac disease that is considered 
eligible for reimbursement.
Need for palliative care for people living with 
heart failure in Poland According to recent 
data, the number of people living with diag‑
nosed HF in Poland is estimated as 744 500 cas‑
es in 2017, whereas 133 900 new cases are diag‑
nosed and reported to the NFZ database every 
year.87 More than 80% of patients with newly di‑
agnosed HF are over the age of 65 years.89 Ac‑
cording to NFZ, 194 039 people diagnosed with 
HF were hospitalized in 2017. The total number 
of HF ‑related hospitalizations is continuous‑
ly growing, approximately with a 1.1% increase 
per year, and reached 227 483 hospitalizations 
in 2017.87 The estimated incidence of advanced 
HF in different studies and populations ranged 
from 2% to 5% of all patients with diagnosed 
HF.89-92 Based on these data, it can be assumed 
that about 26 000 people in Poland suffer from 
advanced HF. The number of people living with 
end ‑stage HF in Poland can be expected to reach 
28 000 cases in 2025 if the treatment of HF in 
everyday practice does not change significantly.
Proposed structures of care for people liv-
ing with cardiac disease who have palliative 
care needs High ‑quality PC should be deliv‑
ered in any place where patients receive care: 
at home, in long ‑term care facilities, or in any 
inpatient unit including general, cardiology, or 
intensive care units. Care can be provided, de‑
pending on patient’s needs and place of care, by 
general practitioners, internists, geriatric spe‑
cialists, cardiologists, or PC specialists, closely 
cooperating with other disciplines if needed.2 
Primarily, integrating PC in the patient care, 
and not transferring patients to the PC units, 
is the current paradigm of providing PC in pa‑
tients with cardiac disease.57,93-95 The optimal 
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